Belimumab in a Patient with Systemic Lupus Erythematosus with Juvenile Onset and Steroid-induced Diabetes: Clinical Case

Background. The management of children with systemic lupus erythematosus (SLE) is usually associated with lifelong systemic glucocorticoids administration and, thereby, high risk of serious side effects, including steroid-induced diabetes. The belimumab (B-lymphocyte stimulator inhibitor) administration significantly reduces the glucocorticoids dose, the risk and severity of steroid therapy complications. Clinical case description. The patient was diagnosed with SLE at the age of 16 years. Therapy with hydroxychloroquine and oral glucocorticoid at a high dose (methylprednisolone 56 mg per day) was initiated. Steroid-induced diabetes was diagnosed 1 month after the therapy start; avascular necrosis sites were revealed in 2 months. Mycophenolate mofetil made it possible to achieve the disease activity control. However, the belimumab was prescribed 5 months after diagnosis verification due to continuous insulin requirement and avascular necrosis progression. Conclusion. Belimumab is the only genetically engineered biologic drug approved for the treatment of children with SLE. As a result of its use, it was possible to stabilize the patient's condition quickly (within 3 months), to reduce significantly the dose of oral glucocorticoid, methylprednisolone (from 24 to 8 mg/day), to achieve remission of steroidinduced diabetes with further insulin withdrawal, and also to relieve avascular necrosis clinical symptoms.

1. das Chagas Medeiros MM, Bezerra MC, Braga FN, et al. Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE. Lupus. 2016;25(4):355–363. doi: https://doi.org/10.1177/0961203315606983

2. Aseeva EA, Lila AM, Soloviev SK, et al. Clinical and immunological phenotypes of systemic lupus erythematosus, identified based on cluster analysis of data from 400 patients from V.A. Nasonova Research Institute of Rheumatology. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2022;16(5):13–21. (In Russ). doi: https://doi.org/10.14412/1996-7012-2022-5-13-21

3. Hoffman IE, Lauwerys BR, De Keyser F, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009;68(3):412–415. doi: https://doi.org/10.1136/ard.2008.094813

4. Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther. 2020;14:2503–2513. doi: https://doi.org/10.2147/DDDT.S216193

5. Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) — Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488–504. doi: https://doi.org/10.1016/j.berh.2018.02.001

6. Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367–383. (In Russ). doi: https://doi.org/10.47360/1995-4484-2021-367-383

7. Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10–17. doi: https://doi.org/10.1177/0961203314547793

8. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021;23(4):331–347. doi: https://doi.org/10.1007/s40272-021-00457-z

9. Kaleda MI, Nikishina IP, Nikolaeva EV, et al. Rituximab for rheumatic diseases in children: Results of a retrospective study of the safety of therapy. Nauchcno-Practicheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):208–214. (In Russ). doi: https://doi.org/10.47360/1995-4484-2021-208-214

10. Chen F, Zheng Y, Chen X, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022; 13:940416. doi: https://doi.org/10.3389/fimmu.2022.940416

11. Brunner HI, Abud-Mendoza C, Viola DO, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340–1348. doi: https://doi.org/10.1136/annrheumdis-2020-217101

12. Fontana F, Alfano G, Leonelli M, et al. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. BMC Nephrol. 2018;19(1):276. doi: https://doi.org/10.1186/s12882-018-1066-3

13. Zeng HQ, Lu XP, Yan ZB, Ye ZZ. First case presentation of refractory pediatric bullous lupus erythematosus (BSLE) treatment with belimumab. Eur Rev Med Pharmacol Sci. 2022;26(21):7980– 7985. doi: https://doi.org/10.26355/eurrev_202211_30151

14. Wang D, Shan C, Liu J, et al. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study. Front Immunol. 2022;13:1067721. doi: https://doi.org/10.3389/fimmu.2022.1067721

15. Suh S, Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. Endocrinol Metab (Seoul). 2017;32(2):180–189. doi: https://doi.org/10.3803/EnM.2017.32.2.180

16. Bao S, Huang H, Jin Y, et al. Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus. Lupus Sci Med. 2023;10(1):e000834. doi: https://doi.org/10.1136/lupus-2022-000834

17. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(5):809–813. doi: https://doi.org/10.1002/art.1780400506

18. Rella V, Rotondo C, Altomare A, et al. Bone Involvement in Systemic Lupus Erythematosus. Int J Mol Sci. 2022;23(10):5804. doi: https://doi.org/10.3390/ijms23105804

19. Yang Y, Kumar S, Lim LS, et al. Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus. J Rheumatol. 2015;42(12):2304–2349. doi: https://doi.org/10.3899/jrheum.150464

20. Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017;76(11):1788–1796. doi: https://doi.org/10.1136/annrheumdis-2016-210960

21. Alexeeva EI, Dvoryakovskaya TM, Nikishina IP, et al. Systemic Lupus Erythematosus: Clinical Recommendations. Part 2. Voprosy sovremennoi pediatrii — Current Pediatrics. 2018;17(2): 110–125. (In Russ). doi: https://doi.org/10.15690/vsp.v17i2.1877

22. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. doi: https://doi.org/10.1136/annrheumdis-2019-215089

23. Hammam N, Evans M, Bell CF, et al. Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry. ACR Open Rheumatol. 2022;4(10):883–889. doi: https://doi.org/10.1002/acr2.11482

24. Massias JS, Smith EM, Al-Abadi E, et al. Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021;30(4):597–607. doi: https://doi.org/10.1177/0961203320984251

25. Lim LSH, Pullenayegum E, Lim L, et al. From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(11):1627–1635. doi: https://doi.org/10.1002/acr.23199

26. Malagón C, Gomez MDP, Mosquera C, et al. Juvenile polyauto-immunity in a rheumatology setting. Autoimmun Rev. 2019;18(4): 369–381. doi: https://doi.org/10.1016/j.autrev.2018.11.006

27. Setoue DN, Pitta AC, Fiorot FJ, et al. Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Symptomatic polyautoimmunity at diagnosis of 1463 childhood-onset lupus: A Brazilian multicenter study. Autoimmun Rev. 2018;17(8): 836–839. doi: https://doi.org/10.1016/j.autrev.2018.03.009

28. Heshin-Bekenstein M, Trupin L, Yelin E, et al. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019;49(2):267–272. doi: https://doi.org/10.1016/j.semarthrit.2019.05.010

29. Nakamura J, Saisu T, Yamashita K, et al. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum. 2010;62(2):609–615. doi: https://doi.org/10.1002/art.27236

30. Tsai HL, Chang JW, Lu JH, Liu CS. Epidemiology and risk factors for avascular necrosis in childhood systemic lupus erythematosus in a Taiwanese population. Sci Rep. 2020;10(1):15563. doi: https://doi.org/10.1038/s41598-020-71923-w

31. Kallas R, Li J, Petri M. Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study. Arthritis Care Res (Hoboken). 2022;74(7):1122–1132. doi: https://doi.org/10.1002/acr.24541

32. Kunyakham W, Foocharoen C, Mahakkanukrauh A, et al. Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Pac J Allergy Immunol. 2012;30(2):152–157.

33. Nevskaya T, Gamble MP, Pope JE. A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol. 2017;35(4):700–710.

34. Sakamoto M, Shimizu K, Iida S, et al. Osteonecrosis of the femoral head: a prospective study with MRI. J Bone Joint Surg Br. 1997;79(2): 213–219. doi: https://doi.org/10.1302/0301-620x.79b2.7179

35. Gurion R, Tangpricha V, Yow E, et al. Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatr Rheumatol Online J. 2015;13:13. doi: https://doi.org/10.1186/s12969-015-0008-x36.

36. Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2015;42(12):2288–2295. doi: https://doi.org/10.3899/jrheum.150470